Presented By Christina Tsien at 2014 ASCO Annual Meeting

Current Limitations in the Response Assessment of Anti-Angiogenic Therapy

Presented By Christina Tsien at 2014 ASCO Annual Meeting

Imaging Changes Following Anti-Angiogenic Therapy

Presented By Christina Tsien at 2014 ASCO Annual Meeting

Does Reduction in Enhancement Reflect Anti-Tumor Effect?

Presented By Christina Tsien at 2014 ASCO Annual Meeting

Recurrent GBM treated with Bevacizumab: CE-Δ T1-weighted Subtraction Maps Aid Prediction of Survival in a Multi-Center Clinical Trial

Presented By Christina Tsien at 2014 ASCO Annual Meeting

Improved Response Rates with Anti-Angiogenic Therapies Does Not Correlate to Improved OS

Presented By Christina Tsien at 2014 ASCO Annual Meeting

<br />Physiologic MRI: Imaging Tumor Biology May Improve Response Assessment

Presented By Christina Tsien at 2014 ASCO Annual Meeting

Slide 8

Presented By Christina Tsien at 2014 ASCO Annual Meeting

Bi-modal fitted ADC Histogram Analysis Predict 6 mth PFS in Recurrent GBM Tx with Bevacizumab

Presented By Christina Tsien at 2014 ASCO Annual Meeting

Bevacizumab Decreases Edema Leading to Improved Clinical Benefit

Presented By Christina Tsien at 2014 ASCO Annual Meeting

Vessel Architectural Imaging

Presented By Christina Tsien at 2014 ASCO Annual Meeting

Summary

Presented By Christina Tsien at 2014 ASCO Annual Meeting

Imaging Biomarkers Ready for Prime Time?

Presented By Christina Tsien at 2014 ASCO Annual Meeting

Physiologic Imaging Biomarkers must add value beyond known Clinical Predictors of OS

Presented By Christina Tsien at 2014 ASCO Annual Meeting

What are the Challenges in Incorporating Imaging Biomarkers in the Clinic Today?

Presented By Christina Tsien at 2014 ASCO Annual Meeting

Diffusion MRI

Presented By Christina Tsien at 2014 ASCO Annual Meeting

Summary

Presented By Christina Tsien at 2014 ASCO Annual Meeting